T-cell receptor recognizing EO2463 peptides (TCR (EO2463-specific))

The T-cell receptor (TCR) recognizing EO2463 peptides is the functional target of the EO2463 immunotherapy, a novel OncoMimic vaccine designed for B-cell malignancies (Enterome, 2023; NCI Drug Dictionary). This specific TCR population belongs to pre-existing memory CD8+ T cells that were initially primed by commensal gut bacteria (Enterome, 2023). The EO2463 vaccine utilizes molecular mimicry by providing synthetic peptides that closely resemble epitopes of B-cell lineage markers, specifically CD20, CD22, CD37, and CD268 (BAFF receptor) (ASH Publications, 2024). When these peptides are presented on HLA-A2 molecules, they are recognized by the TCRs, triggering a robust expansion of cytotoxic T lymphocytes (ASH Publications, 2024). These activated T cells then cross-react with the native human antigens on the surface of malignant B cells, leading to targeted tumor cell lysis (Enterome, 2023). This approach is currently being evaluated in clinical trials for indolent non-Hodgkin lymphomas, such as follicular lymphoma and marginal zone lymphoma (ClinicalTrials.gov, NCT04669171). Clinical data suggest that targeting these TCRs can induce meaningful objective responses with a manageable safety profile, primarily characterized by local injection site reactions (ASH Publications, 2024). By leveraging pre-existing immune memory, this target allows for a rapid and potent anti-tumor response without the need for de novo priming (Enterome, 2023).

Other names

EO2463-specific T-cell receptorOncoMimic-reactive T-cell receptorCross-reactive microbial-B-cell T-cell receptorT-cell receptor recognizing OncoMimic peptides

EO2463 provides synthetic microbial-derived peptides that mimic B-cell tumor antigens (CD20, CD22, CD37, and CD268). These peptides are presented by HLA-A2 molecules to specific T-cell receptors on pre-existing memory CD8+ T cells. Upon recognition, these T cells undergo rapid expansion and exert cytotoxic activity against malignant B cells that express the corresponding human antigens through molecular mimicry.